Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year. In December interim phase 1/2 trial results showed ...

Initial phase III trial results from November 2020 suggested that, after two doses, new mRNA vaccines developed by Moderna ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi for COVID-19 vaccines to generate royalties, and reduce selling and ...

The updated mRNA-1273.815 COVID-19 vaccine was significantly protective against hospitalization and medically attended outcomes among adults in the United States.

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Novavax performed well last year, but the company's shares are down significantly over the past three years and are not far ...

Research offering unprecedented insights into global vaccine distribution patterns has found significant disparities in COVID ...

Cornell researchers have developed a stable, multi-target vaccine offering long-lasting protection against COVID-19 and influenza, with promising results in mice. Cornell University researchers have ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...